<DOC>
	<DOCNO>NCT01906125</DOCNO>
	<brief_summary>This study intend establish equivalence 2 formulation intend final market product . The formulation compare capsule give patient phase I II study capsule administer patient phase III trial . Both capsule compare intended final market capsule . The comparison perform look pharmacokinetic parameter define rate extent absorption , Cmax AUC . A statistical analysis perform compare parameter calculate single 125 mg dose 3 capsule identify like significant difference 3 formulation .</brief_summary>
	<brief_title>A Study To Establish The Equivalence Of 2 Palbociclib ( PD-0332991 ) Formulations To The Intended Final Market Product</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Healthy male subject and/or female subject nonchildbearing potential age 18 55 year Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . Any condition possibly affect drug absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Cmax</keyword>
	<keyword>AUC</keyword>
</DOC>